期刊
EPILEPSIA
卷 54, 期 1, 页码 e9-e12出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1528-1167.2012.03654.x
关键词
Bumetanide; Temporal lobe epilepsy; NKCC1; GABA
资金
- cellular and molecular research centre of Tehran University of medical sciences [508]
- Iran National Science Foundation (INSF)
Alterations in the balance of K-Na-2Cl cotransporter (NKCC1) and Na-Cl cotransporter (KCC2) activity may cause depolarizing effect of ?-aminobutyric Acid (GABA), and contribute to epileptogenesis in human temporal lobe epilepsy. NKCC1 facilitates accumulation of chloride inside neurons and favors depolarizing responses to GABA. In the current pilot study we provide the first documented look at efficacy of bumetanide, a specific NKCC1 antagonist, on reduction of seizure frequency in adult patients with temporal lobe epilepsy. According to our results, seizure frequency was reduced considerably in these patients. Furthermore, epileptiform discharges decreased in two of our patients. If the efficacy of bumetanide is proven in large scale studies, it can be used as a supplemental therapy in temporal lobe epilepsy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据